Cargando…

The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression: An Open-Label Trial

Dopaminergic dysfunction is implicated in the pathophysiology of treatment-resistant depression. Although the efficacy of adjunctive pramipexole treatment has been demonstrated in treatment-resistant bipolar depression, such data are scarce for major depressive disorder (MDD). We recruited 17 patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hori, Hiroaki, Kunugi, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Scientific World Journal 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415165/ https://www.ncbi.nlm.nih.gov/pubmed/22919308 http://dx.doi.org/10.1100/2012/372474

Ejemplares similares

Enhanced Taste Recognition Following Subacute Treatment With The Dopamine D2/D3 Receptor Agonist Pramipexole in Healthy Volunteers
por: Kaltenboeck, Alexander, et al.
Publicado: (2022)

Efficacy of low-dose D(2)/D(3) partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study
por: Weng, Jia Jun, et al.
Publicado: (2019)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Barabash, Nadiya Ye., et al.
Publicado: (2022)

The efficacy of memantine in the treatment of civilian posttraumatic stress disorder: an open-label trial
por: Hori, Hiroaki, et al.
Publicado: (2021)

Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release
por: Hauser, Robert A., et al.
Publicado: (2014)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Preliminary Evidence of Efficacy and Target Engagement of Pramipexole in Anhedonic Depression
por: Ventorp, Filip, et al.
Publicado: (2022)

Pramipexole, a dopamine D3/D2 receptor-preferring agonist, attenuates reserpine-induced fibromyalgia-like model in mice
por: Martins, Carlos Pereira, et al.
Publicado: (2021)

Open-label placebos as adjunctive therapy for patients with depression
por: Schienle, Anne, et al.
Publicado: (2022)

An Open-Label Uncontrolled, Multicenter Study for the Evaluation of the Efficacy and Safety of the Dermal Filler Princess VOLUME in the Treatment of Nasolabial Folds
por: Kopera, Daisy, et al.
Publicado: (2015)

Efficacy of pramipexole combined with levodopa for Parkinson’s disease treatment and their effects on QOL and serum TNF-α levels
por: Huang, Jinzhong, et al.
Publicado: (2020)

The Effect of Pramipexole Therapy on Balance Disorder and Fall Risk in Parkinson's Disease at Early Stage: Clinical and Posturographic Assessment
por: Güler, Sibel, et al.
Publicado: (2012)

Pramipexole: new use for an old drug – the potential use of pramipexole in the treatment of restless legs syndrome
por: Benbir, Gulcin, et al.
Publicado: (2006)

Add-on pramipexole for anhedonic depression: study protocol for a randomised controlled trial and open-label follow-up in Lund, Sweden
por: Lindahl, Jesper, et al.
Publicado: (2023)

Pramipexole in the Treatment of Refractory Depression in a Patient with Rapid Cycling Bipolar Disorder
por: Hegde, Aditya, et al.
Publicado: (2015)

Update on the use of pramipexole in the treatment of Parkinson’s disease
por: Constantinescu, Radu
Publicado: (2008)

Dyskinesias and Treatment with Pramipexole in Patients with Parkinson's Disease
por: Piedad, John C. P., et al.
Publicado: (2012)

S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study
por: De Berardis, Domenico, et al.
Publicado: (2013)

Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study)
por: Azim, Lumbini, et al.
Publicado: (2021)

Comparative Analysis of the Effects of Escitalopram, Pramipexole, and Transcranial Magnetic Stimulation on Depression in Patients With Parkinson Disease: An Open-Label Randomized Controlled Trial
por: Chen, Jing, et al.
Publicado: (2022)

Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients
por: Deutschländer, Angela, et al.
Publicado: (2016)

Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson's Disease
por: Seiple, William, et al.
Publicado: (2016)

Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study
por: Fornaro, Michele, et al.
Publicado: (2013)

Rifaximin Is Effective for the Treatment of Clostridium difficile—Associated Diarrhea: Results of an Open-Label Pilot Study
por: Rubin, David T., et al.
Publicado: (2011)

Efficacy of Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis: an open-label dose-ranging study
por: Rhein, Joshua, et al.
Publicado: (2016)

Efficacy and timing of adjunctive therapy in the anti-VEGF treatment regimen for macular oedema in retinal vein occlusion: 12-month real-world result
por: Lip, P L, et al.
Publicado: (2018)

Dopamine Dysregulation Syndrome in Parkinson’s Disease Patients with Unsatisfactory Switching from Immediate to Extended Release Pramipexole: A Further Clue to Incentive Sensitization Mechanisms?
por: Solla, Paolo, et al.
Publicado: (2013)

Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents
por: Garoon, Robert B., et al.
Publicado: (2016)

The Efficacy and Safety of the Chinese Herbal Formula, JTTZ, for the Treatment of Type 2 Diabetes with Obesity and Hyperlipidemia: A Multicenter Randomized, Positive-Controlled, Open-Label Clinical Trial
por: Yu, Xiaotong, et al.
Publicado: (2018)

Comparison of pramipexole and citalopram in the treatment of depression in Parkinson's disease: A randomized parallel-group trial
por: Ziaei, Ehsan, et al.
Publicado: (2022)

Efficacy and safety of non‐ergot dopamine‐receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: A network meta‐analysis
por: Chen, Xiang‐Ting, et al.
Publicado: (2022)

Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning
por: Fava, Maurizio, et al.
Publicado: (2016)

Dopamine D2R Agonist-Induced Cardiovascular Effects in Healthy Male Subjects: Potential Implications in Clinical Settings
por: Abou Farha, Khalid, et al.
Publicado: (2014)

Efficacy of Vitamin E in Methotrexate-Induced Hepatotoxicity in Rheumatoid Arthritis: An Open-Label Case-Control Study
por: Vaidya, Binit, et al.
Publicado: (2020)

Efficacy of an adjunctive brief psychodynamic psychotherapy to usual inpatient treatment of depression: rationale and design of a randomized controlled trial
por: Ambresin, Gilles, et al.
Publicado: (2012)

The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)

PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression
por: Au-Yeung, Sheena Kristine, et al.
Publicado: (2022)

Beneficial effect of pramipexole for motor function and depression in Parkinson’s disease
por: Kano, Osamu, et al.
Publicado: (2008)

SUN-303 Effects of Open-Label, Adjunctive Ganaxalone Treatment on Resistant Depression in Postmenopausal Women: A Pilot Study
por: Dichtel, Laura E, et al.
Publicado: (2020)

The Depression Anxiety Stress Scale 8-Items Expresses Robust Psychometric Properties as an Ideal Shorter Version of the Depression Anxiety Stress Scale 21 Among Healthy Respondents From Three Continents
por: Ali, Amira Mohammed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m7kda9ndfnjdio5h9qg6kebm42